Last reviewed · How we verify
GSK716155 subcutaneous injections — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK716155 subcutaneous injections (GSK716155 subcutaneous injections) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK716155 subcutaneous injections TARGET | GSK716155 subcutaneous injections | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK716155 subcutaneous injections CI watch — RSS
- GSK716155 subcutaneous injections CI watch — Atom
- GSK716155 subcutaneous injections CI watch — JSON
- GSK716155 subcutaneous injections alone — RSS
Cite this brief
Drug Landscape (2026). GSK716155 subcutaneous injections — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk716155-subcutaneous-injections. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab